The prognosis of patients affected by metastatic renal cell carcinoma (mRCC) has improved
markedly with targeted therapies. Unfortunately, 20–25% of the patients are refractory to …

BACKGROUND The current study was conducted to investigate the dependence between
progression‐free survival (PFS) and overall survival (OS) in patients with metastatic renal …

Metastatic renal carcinoma concerns 30 to 50% of patients. The principal localisations are
lung, liver, bone and brain. In case of unique localisation the treatment is almost surgical …

Background: The most important prognostic factors for survival in patients with metastatic
renal cell carcinoma (mRCC) were evaluated in the era of cytokine therapy, and only …

The worldwide incidence of kidney cancer is estimated at 337,860 new cases per year in the
International Agency for Research on Cancer's GLOBOCAN 2012 update, with an estimated …

The management of metastatic renal cell carcinoma has undergone a dramatic evolution in
the past year, marked by the approval of two drugs by the US Food and Drug Administration …

PURPOSE:: The minimal efficacy of standard therapy for metastatic renal cell carcinoma
(RCC) has resulted in the evaluation of numerous novel agents. Some agents have shown …

Background The use of third-line targeted therapy (TTT) in metastatic renal cell carcinoma
(mRCC) is not well characterized and varies due to the lack of robust data to guide treatment …

Conventional chemotherapy is associated with poor outcomes in metastatic renal cell
carcinoma (RCC). Advances in the understanding of tumor molecular biology and the …

Background: Vascular endothelial growth factor (VEGF) inhibitors, including targeted
therapy with tyrosine kinase inhibitors (TKIs) and the angiogenesis inhibitor bevacizumab …